All In Biotech

Drug Trial Radar · NCT07389733

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-6208 in Combination With HRS-8080 ± HRS-6209, or in Combination With Fulvestrant ± HRS-6209, or in Combination With Letrozole ± HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer: an Open Label, Multicenter, Phase Ib/II Study

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 27, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.

Conditions

  • Advanced Unresectable or Metastatic Breast Cancer of Adults

Interventions

  • HRS-6208 CapsuleDrug

    HRS-6208 capsule.

  • HRS-6209 CapsuleDrug

    HRS-6209 capsule.

  • HRS-8080 TabletDrug

    HRS-8080 tablet.

  • Fulvestrant injectionDrug

    Fulvestrant injection.

  • Letrozole tabletsDrug

    Letrozole tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: The DLT will be evaluated for the last participant in each dose group 28 days after the first dose.
  2. Recommended phase II dose (RP2D)Time frame: The evaluation of RP2D will be completed approximately one year later than DLT evaluation.
  3. Incidence and severity of adverse events (AEs)Time frame: Each individual participant will be followed for approximately 8 months, and the entire study process will last for approximately 36 months.
  4. Objective response rate (ORR)Time frame: For a single subject, the duration will be approximately 8 months, while the entire research process will last for 36 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.